For the study, researchers examined people, aged 50 years and older at up to six visits. They studied 884 who were taking PPIs at every patient visit; 1,925 who took PPIs intermittently; and 7,677 never reported taking PPIs. The study participants either had normal cognition or mild cognitive impairment.
The study shows continuous or intermittent PPI use was linked to a decreased risk of decline in cognitive function as well as lower risk of developing Alzheimer’s disease.
“Proton pump inhibitors were not associated with greater risk of dementia or of AD, in contrast to recent reports,” the study authors conclude.
More articles on infection control:
Hudson Headwaters Health Network employee diagnosed with measles
3 things to know about the next zoonotic pandemic
A new warrior in the sepsis fight: Dedicated sepsis nurses
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.